Matsumoto et al. proposed that exosome-derived miRNAs can be used as a prognostic tool for HF in patients with AMI and elevated levels of p53-responsive miRNAs (34a, 192, and 194)18 days after AMI among patients experiencing HF within 1 year [37]. This evidence concerns the gene TP53 and hydrops fetalis.